Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
2.520
-0.080 (-3.08%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.012.370.020.01
Research & Development
2.241.570.830.13
Operating Expenses
12.243.940.850.14
Operating Income
-12.24-3.94-0.85-0.14
Interest Expense
-4.34-1.64--
Interest & Investment Income
0.05---
EBT Excluding Unusual Items
-16.53-5.59-0.85-0.14
Other Unusual Items
--7.49--
Pretax Income
-16.53-13.07-0.85-0.14
Net Income
-16.53-13.07-0.85-0.14
Net Income to Common
-16.53-13.07-0.85-0.14
Shares Outstanding (Basic)
302727-
Shares Outstanding (Diluted)
302727-
Shares Change (YoY)
8.18%1.77%--
EPS (Basic)
-0.56-0.48-0.03-
EPS (Diluted)
-0.56-0.48-0.03-
EBIT
-12.24-3.94-0.85-0.14
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q